essential step for titration of vaccinia immunoglobulins and smallpox vaccines development of anti-vaccinia immunoglobulins for the treatment of severe side effects following vaccination

We have chosen to develop and validate the "gold standard method" (plaque reduction neutralization assay) to titrate neutralizing anti-vaccinia antibodies in two different French laboratories belonging to the Department of Defense (CRSSA) and to the French Health Products Safety Agency (Afssaps). The results of precision, linearity and accuracy of the method led to consider the method as validated. In parallel, we have prepared and lyophilized a pool of anti-vaccinia plasma samples issued from a unique donor and qualified this preparation versus the first British standard to use it as an in-house standard with a titer of 25 international units (IU). This work will allow to titrate, in IU, sera from vaccinated persons in order (i) to titrate purified anti-vaccinia immunoglobulin preparations for vaccine severe side effect treatments; (ii) to investigate the level of neutralizing antibodies in the general population; and (iii) to investigate clinical trials of new generation smallpox vaccines. In the future, this will allow comparability of studies on either smallpox vaccines or on the serological status of the population.with the Haemophilus influenzae type b (Hib) polysaccharide capsule (PRP) was evaluated in a group of 10 children and nine adults.

chitosan supplement  responded to parenteral vaccination with an increase in serum anticapsular antibody. The children's preimmunization anti-PRP antibody level (mean = 0.04 microgram/ml) and 3 wk postimmunization level (mean = 19.3 micrograms/ml) were lower than the adults' (preimmunization mean = 1.5 microgram/ml; postimmunization mean = 81.2 micrograms/ml). Eight of 10 children and seven of nine adults also developed a rise in antibody in nasal secretions.

The children's mean nasal preimmunization level was 0.74 microgram/mg IgA and mean postimmunization level was 5.0 micrograms/mg IgA. The adults' mean nasal preimmunization level was 0.98 microgram/mg IgA and mean postimmunization level was 3.0 micrograms/mg IgA. Salivary antibody responses generally followed the pattern of nasal antibody responses.

These data suggest that parenteral administration with the Hib capsular polysaccharide can produce a mucosal antibody response. Furthermore, although serum antibody responses to PRP vaccination are greater in adults than in children, mucosal antibody responses are comparable.vaccines against coronavirus disease of 2019 (COVID-19). Immunogenicity is a determinant of the efficacy and safety of vaccines. This systematic review and associated meta-analysis summarized and characterized the immunogenicity of COVID-19 vaccines in randomized controlled trials (RCTs). METHODS: Relevant RCTs were systematically sourced from different medical databases in August 2021. The risk ratios and mean differences with 95% confidence intervals were calculated.

RESULTS: Of 2,310 papers, 16 RCTs were eligible for review. These RCTs involved a total of 26,698 participants (15,292 males and 11,231 females). The pooled results showed a significant difference in the geometric mean titer between the vaccinated and control groups in favor of the vaccine group after 1 and 2 months 0.001). The difference in the older age group (>55y) was insignificant (P = 0.24). The seroconversion rate of spike neutralizing antibodies favored the vaccine groups 1 or 2 months after vaccination (P < 0.

001). The seroconversion rate of the vaccine group was significantly different (P < 0.001) from that of the control group. CONCLUSIONS: Vaccination elicits immunogenicity in the follow-up period for all age groups and at low and large doses. Therefore, people should be encouraged to receive vaccines currently being offered. A boost dose has been asserted for the elderly.10.

1590/0037-8682-0661-2022. eCollection 2023.gamma-1 or gamma-1-type heat-stable globulins and a non-gamma-1 heat-labile challenge with the highly pathogenic influenza A H5N1 virus.influenza A H5N1 pre-pandemic vaccine combined with synthetic double-stranded RNA (polyI/polyC12U) as an adjuvant was examined. The monkeys were immunized with the adjuvant-combined vaccine on weeks 0, 3, and 5, and challenged with the homologous virus 2 weeks after the third immunization.